Chervin Ronald D, Ellenberg Susan S, Hou Xiaoling, Marcus Carole L, Garetz Susan L, Katz Eliot S, Hodges Elise K, Mitchell Ron B, Jones Dwight T, Arens Raanan, Amin Raouf, Redline Susan, Rosen Carol L
Department of Neurology and Sleep Disorders Center, University of Michigan, Ann Arbor, MI.
Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Chest. 2015 Nov;148(5):1204-1213. doi: 10.1378/chest.14-2873.
Adenotonsillectomy (AT) is commonly performed for childhood OSA syndrome (OSAS), but little is known about prognosis without treatment.
The Childhood Adenotonsillectomy Trial (CHAT) randomized 50% of eligible children with OSAS to a control arm (watchful waiting), with 7-month follow-up symptom inventories, physical examinations, and polysomnography. Polysomnographic and symptomatic resolution were defined respectively by an apnea/hypopnea index (AHI) <2 and obstructive apnea index (OAI) <1 and by an OSAS symptom score (Pediatric Sleep Questionnaire [PSQ]) < 0.33 with ≥ 25% improvement from baseline.
After 194 children aged 5 to 9 years underwent 7 months of watchful waiting, 82 (42%) no longer met polysomnographic criteria for OSAS. Baseline predictors of resolution included lower AHI, better oxygen saturation, smaller waist circumference or percentile, higher-positioned soft palate, smaller neck circumference, and non-black race (each P < .05). Among these, the independent predictors were lower AHI and waist circumference percentile < 90%. Among 167 children with baseline PSQ scores ≥ 0.33, only 25 (15%) experienced symptomatic resolution. Baseline predictors were low PSQ and PSQ snoring subscale scores; absence of habitual snoring, loud snoring, observed apneas, or a household smoker; higher quality of life; fewer attention-deficit/hyperactivity disorder symptoms; and female sex. Only lower PSQ and snoring scores were independent predictors.
Many candidates for AT no longer have OSAS on polysomnography after 7 months of watchful waiting, whereas meaningful improvement in symptoms is not common. In practice, a baseline low AHI and normal waist circumference, or low PSQ and snoring score, may help identify an opportunity to avoid AT.
ClinicalTrials.gov; No.: NCT00560859; URL: www.clinicaltrials.gov.
腺样体扁桃体切除术(AT)常用于治疗儿童阻塞性睡眠呼吸暂停综合征(OSAS),但对于未经治疗的预后情况知之甚少。
儿童腺样体扁桃体切除术试验(CHAT)将50%符合条件的OSAS儿童随机分配至对照组(观察等待),并进行为期7个月的随访,包括症状清单、体格检查和多导睡眠图检查。多导睡眠图和症状缓解分别定义为呼吸暂停/低通气指数(AHI)<2且阻塞性呼吸暂停指数(OAI)<1,以及阻塞性睡眠呼吸暂停综合征症状评分(儿童睡眠问卷[PSQ])<0.33且较基线改善≥25%。
194名5至9岁儿童经过7个月的观察等待后,82名(42%)不再符合OSAS的多导睡眠图标准。缓解的基线预测因素包括较低的AHI、较好的血氧饱和度、较小的腰围或百分位数、较高位置的软腭、较小的颈围以及非黑人种族(各P<.05)。其中,独立预测因素为较低的AHI和腰围百分位数<90%。在167名基线PSQ评分≥0.33的儿童中,只有25名(15%)症状得到缓解。基线预测因素为低PSQ和PSQ打鼾子量表评分;无习惯性打鼾、大声打鼾、观察到的呼吸暂停或家庭吸烟者;较高的生活质量;较少的注意力缺陷/多动障碍症状;以及女性性别。只有较低的PSQ和打鼾评分是独立预测因素。
许多腺样体扁桃体切除术的候选者在经过7个月的观察等待后,多导睡眠图检查显示不再患有OSAS,而症状有意义的改善并不常见。在实际操作中,基线低AHI和正常腰围,或低PSQ和打鼾评分,可能有助于确定避免进行腺样体扁桃体切除术的机会。
ClinicalTrials.gov;编号:NCT00560859;网址:www.clinicaltrials.gov。